Every 10-Q that Vivani Medical, Inc. (VANI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VANI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VANI filings page.
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants using its NanoPortal™ technology, focused on GLP-1 and other chronic-disease therapies. It reported a net loss of $6.4 million for the quarter and $13.2 million for the six months ended June 30, 2026, with no product revenue.
Cash and cash equivalents were $19.9 million (plus $0.9 million restricted cash), total assets $41.6 million, and stockholders’ equity $19.0 million. Operating cash outflow was $12.2 million in the first half of 2026, partly offset by $15.5 million of equity financing, including private placements and a registered direct offering. Management estimates existing cash will fund planned operations only through the second quarter of 2027 and explicitly states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
Strategically, Vivani is advancing lead GLP-1 implant candidate NPM-139, has fully enrolled and dosed the SLIM-1 trial with topline data expected November 2026, and entered a non-exclusive evaluation agreement with Novo Nordisk. Vivani is also pursuing a merger of its neurostimulation subsidiary Cortigent with ClearOne, under which Vivani would receive 12,500,000 ClearOne shares and is expected to remain majority owner of the combined Cortigent-focused entity.
Vivani Medical reported a net loss of $6.8 million for the quarter ended March 31, 2026, slightly higher than the $6.3 million loss a year earlier as it advanced its clinical-stage implant programs.
Research and development expenses were $4.4 million and general and administrative costs were $2.4 million, both up about 4% year over year. Cash, cash equivalents and restricted cash totaled $21.1 million, including $19.7 million of cash and cash equivalents, supported by $9.7 million of net financing inflows in the quarter from private sales and a registered direct offering.
The company estimates its current capital, plus remaining committed equity financings, can fund operations into mid‑2027, but additional capital will be needed beyond that as it continues developing its NanoPortal-based GLP‑1 implant candidates and works to separate its Cortigent neurostimulation business.
Vivani Medical (VANI) filed its Q3 2025 10-Q, reporting continued operating investment as it advances subdermal GLP-1 implant programs. Cash and cash equivalents were $2.6 million at September 30, 2025, down from $18.4 million at year-end, with total assets of $25.0 million and stockholders’ equity of $1.3 million. Net loss was $6.5 million for the quarter and $20.0 million year-to-date, driven by R&D and G&A expenses.
The company highlighted clinical and portfolio progress: LIBERATE-1, the first-in-human study of its NanoPortal technology, met primary objectives with a positive safety and tolerability profile, informing plans to prioritize NPM-139 (semaglutide implant). Vivani outlined plans to initiate a Phase 1 study for NPM-139 in the first half of 2026, pending regulatory clearance. To support operations, Vivani entered equity purchase agreements expected to bring $18.6 million between September 30, 2025 and July 15, 2026, and subsequently raised approximately $6.0 million in a private placement and $9.7 million gross in a registered direct offering in October. Shares outstanding were 72,952,235 as of November 12, 2025.
Vivani Medical reported a widening net loss of $13.4 million for the six months ended June 30, 2025 versus $11.4 million a year earlier, driven by higher R&D and general and administrative expenses. Cash and cash equivalents declined to $6.8 million at June 30, 2025 from $18.4 million at December 31, 2024, total assets fell to $28.9 million from $41.6 million, and stockholders' equity decreased to $4.9 million.
The company progressed its NanoPortal GLP-1 implant programs: the LIBERATE-1 first-in-human trial achieved full enrollment and the first implant administration with positive safety, tolerability and encouraging performance signals, prompting prioritization of NPM-139 (semaglutide implant) toward clinical development. Vivani also filed to spin off Cortigent and secured $21.25 million of committed equity purchase agreements beginning September 2025, and believes currently available cash will fund planned obligations for at least the next twelve months.